Date: 2012-12-12
Type of information: Fundraising
Company: Biocartis (Belgium)
Investors: PMV (Belgium) RMM Valiance (UK) Debiopharm Group (Switzerland) Korys (investment holding of the Colruyt family) Philips (The Netherlands) Johnson & Johnson Development Corporation - JJDC (USA) the family office of Dr Paul Janssen, Luc Verelst, Benauca, Rudi Pauwels, founder of Biocartis, New Rhein Healthcare (USA)
Amount: € 34.5 million
Funding type: Series D financing round
Planned used: These funds will be used to commercialize recently launched DMAT platform, validate APOLLO platform and build proprietary oncology content on both platforms.
Others: Biocartis, a molecular diagnostics company developing and commercializing platforms and clinically relevant oncology assays, has announced the completion of a €34,5 million (approximately $45 million, CHF 42 million) Series D equity fund raising entirely backed by existing investors. The round was led by the Flemish investment company PMV (using its TINA-fund), and included RMM (Rudi Mariën), Valiance, Debiopharm Group™, Korys (investment holding of the Colruyt family), Philips, Johnson & Johnson Development Corporation (JJDC), the family office of Dr Paul Janssen, Luc Verelst, Benaruca (Rudi Pauwels, founder of Biocartis) and New Rhein Healthcare (Greg Parekh, CEO). Following the fundraising, Roald Borré, representing PMV, will join the Biocartis Board.
Biocartis is a rapidly growing company; to date Biocartis staff includes over 140 people. Biocartis SA is based at the EPFL's Innovation Square in Lausanne, Switzerland; the Belgian entity which counts over 100 staff, is located in Mechelen. The company raised in total close to € 150 million in equity.
Therapeutic area: Cancer - Oncology
